Uses of aldose-1-epimerase (mutarotase) for diagnosis and therapy of inflammatory diseases and sepsis
First Claim
Patent Images
1. Use of aldose 1-epimerase (A1E) from body fluids or body tissues in human and veterinary medicine as a marker peptide for diagnosis, for prognosis of the course and for monitoring of the course of inflammations and infections and/or as a target for therapeutically influencing the course of inflammations and/or infections.
2 Assignments
0 Petitions
Accused Products
Abstract
Uses of aldose 1-epimerase (SEQ ID NO:3) from body fluids or body tissues in human and veterinary medicine as a marker peptide for diagnosis, for prognosis of the course and for monitoring of the course of inflammations and infections and/or as a target for therapeutically influencing the course of inflammations and/or infections.
-
Citations
15 Claims
- 1. Use of aldose 1-epimerase (A1E) from body fluids or body tissues in human and veterinary medicine as a marker peptide for diagnosis, for prognosis of the course and for monitoring of the course of inflammations and infections and/or as a target for therapeutically influencing the course of inflammations and/or infections.
-
3. Method for differential early diagnosis and detection, for prognosis of the course and assessment of the severity and for therapy-accompanying assessment of the course of sepsis and severe infections, in particular sepsis-like systemic infections, characterized in that the presence and/or amount of human aldose 1 -epimerase (SEQ ID NO:
- 3) in a biological fluid or a tissue sample of a patient is determined and conclusions are drawn from the detectability and/or amount thereof with regard to the presence, the expected course, the severity or the success of a therapy of the sepsis or of infection.
- View Dependent Claims (4, 5, 6, 7, 8, 9, 15)
-
11. Pharmaceutical composition for the treatment of inflammations, including systemic inflammations, characterized in that it comprises aldose 1-epimerase or a functional partial peptide thereof and a pharmaceutically acceptable carrier.
-
12. Pharmaceutical composition for the treatment of inflammatory and other stress reactions of the body, characterized in that it contains antibodies produced against aldose 1-epimerase or aldose 1-epimerase fragments or processed aldose 1 -epimerase and prepared for administration to patients, together with a suitable pharmaceutical carrier.
-
13. Pharmaceutical composition for the treatment of inflammatory diseases of the body, in particular systemic inflammations, or of inflammations caused by infection, in which there is the danger of a systemic spread, characterized in that it contains an active substance which completely or partly inhibits the enzyme activity of aldose 1-epimerase and a suitable pharmaceutical carrier.
-
14. lmmunoadsorbent which has a solid phase for the selective binding of aldose 1-epimerase from the blood circulation of a patient, for the treatment of inflammations and sepsis.
Specification